All In Biotech

Drug Trial Radar · NCT07422610

Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment

A Phase 1b, Open-Label, Multicenter Study to Evaluate the Pharmacokinetic Profile of Pelabresib (DAK539/CPI-0610) in Patients With Advanced Malignancies and Hepatic Impairment

Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

May 19, 2026

Primary completion

Jun 28, 2028

Study completion Aug 2, 2028

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Feb 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to evaluate the impact of hepatic function on the pharmacokinetic (PK) profile of pelabresib in participants with advanced malignancies who have either hepatic impairment (HI) or normal liver function. To reduce participant burden and maximize benefit, the PK of pelabresib will be assessed at steady-state rather than after a single dose, avoiding treatment-free washout periods.

Conditions

  • Advanced Malignancies and Hepatic Impairment

Interventions

  • pelabresibDrug

    pelabresib 125 mg orally (PO) once daily (QD) for 14 days, followed by a 7-day break

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Curve from 0 to 24 hours on Day 14 (AUC₀-24h,D14) of pelabresib at steady state per study groupTime frame: Cycle 1 Day 14: 0, 0.5, 1, 2, 4, 6, 8, and 12 hours postdose (1 cycle = 21 days)
  2. Maximum Plasma Concentration on Day 14 (Cmax,D14) of pelabresib at steady state per study groupTime frame: Cycle 1 Day 14 (1 cycle = 21 days)
  3. Apparent Clearance (CL/F) of pelabresib at steady state per study groupTime frame: Cycle 1 Day 14 (1 cycle = 21 days)
  4. Apparent Volume of Distribution (V/F) of pelabresib at steady state per study groupTime frame: Cycle 1 Day 14 (1 cycle = 21 days)
  5. Terminal Half-Life (T½) of pelabresib at steady state per study groupTime frame: Cycle 1 Day 14 (1 cycle = 21 days)

Locations

10 sites in 4 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Bordeaux, France · Recruiting

  • Novartis Investigative Site

    Saint-Herblain, France · Recruiting

  • Novartis Investigative Site

    Milan, MI, Italy · Recruiting

  • Novartis Investigative Site

    Milan, MI, Italy · Recruiting

  • Novartis Investigative Site

    Candiolo, TO, Italy · Recruiting

  • Novartis Investigative Site

    Barcelona, Spain · Recruiting

  • Novartis Investigative Site

    Madrid, Spain · Recruiting

  • Novartis Investigative Site

    Madrid, Spain · Recruiting

  • Novartis Investigative Site

    Pozuelo de Alarcón, Madrid, Spain · Recruiting

  • Novartis Investigative Site

    London, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.